NPCE NeuroPace Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NPCE

Price (delayed)

$13.9

Market cap

$393.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.27

Enterprise value

$448.21M

Based in Mountain View, Calif., NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating ...

Highlights
NeuroPace's gross profit has increased by 48% YoY and by 11% from the previous quarter
NPCE's revenue is up by 44% year-on-year and by 9% since the previous quarter
NPCE's equity is down by 41% year-on-year but it is up by 26% since the previous quarter
NeuroPace's quick ratio has decreased by 37% YoY and by 14% QoQ
The debt has increased by 3.8% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.neuropace.com
Peers: OBIO OM

Key stats

What are the main financial stats of NPCE
Market
Shares outstanding
28.34M
Market cap
$393.99M
Enterprise value
$448.21M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.69
Price to sales (P/S)
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.85
Earnings
Revenue
$65.42M
EBIT
-$24.44M
EBITDA
-$22.83M
Free cash flow
-$19.87M
Per share
EPS
-$1.27
Free cash flow per share
-$0.77
Book value per share
$0.79
Revenue per share
$2.53
TBVPS
$4.16
Balance sheet
Total assets
$107.65M
Total liabilities
$87M
Debt
$72.4M
Equity
$20.65M
Working capital
$76.49M
Liquidity
Debt to equity
3.51
Current ratio
5.71
Quick ratio
4.86
Net debt/EBITDA
-2.37
Margins
EBITDA margin
-34.9%
Gross margin
73.6%
Net margin
-50.4%
Operating margin
-41.5%
Efficiency
Return on assets
-31.7%
Return on equity
-153.8%
Return on invested capital
-16.1%
Return on capital employed
-26.7%
Return on sales
-37.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NPCE stock price

How has the NeuroPace stock price performed over time
Intraday
-0.5%
1 week
7.01%
1 month
8.68%
1 year
181.38%
YTD
34.82%
QTD
5.3%

Financial performance

How have NeuroPace's revenue and profit performed over time
Revenue
$65.42M
Gross profit
$48.12M
Operating income
-$27.17M
Net income
-$32.96M
Gross margin
73.6%
Net margin
-50.4%
NeuroPace's operating margin has soared by 54% YoY and by 22% from the previous quarter
The net margin has soared by 51% YoY and by 20% from the previous quarter
NeuroPace's gross profit has increased by 48% YoY and by 11% from the previous quarter
NPCE's revenue is up by 44% year-on-year and by 9% since the previous quarter

Growth

What is NeuroPace's growth rate over time

Valuation

What is NeuroPace stock price valuation
P/E
N/A
P/B
17.69
P/S
5.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.85
NeuroPace's EPS has increased by 34% YoY and by 15% QoQ
The price to book (P/B) is 86% higher than the last 4 quarters average of 9.5
NPCE's equity is down by 41% year-on-year but it is up by 26% since the previous quarter
NPCE's price to sales (P/S) is 72% more than its last 4 quarters average of 3.2
NPCE's revenue is up by 44% year-on-year and by 9% since the previous quarter

Efficiency

How efficient is NeuroPace business performance
NeuroPace's ROE has plunged by 58% YoY
NeuroPace's return on sales has surged by 57% YoY and by 24% QoQ
NPCE's ROIC is up by 32% year-on-year and by 15% since the previous quarter
The company's return on assets rose by 19% YoY and by 12% QoQ

Dividends

What is NPCE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NPCE.

Financial health

How did NeuroPace financials performed over time
NPCE's total assets is 24% higher than its total liabilities
NeuroPace's quick ratio has decreased by 37% YoY and by 14% QoQ
The company's current ratio fell by 36% YoY and by 13% QoQ
NeuroPace's debt to equity has surged by 75% YoY but it has decreased by 20% QoQ
NPCE's equity is down by 41% year-on-year but it is up by 26% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.